Mounjaro dosages: what the six UK strengths mean for your treatment

Why the decision about dosage isn't yours to make alone

This is the question most people are actually asking when they search Mounjaro dosages: not just the numbers, but who decides and why. The answer matters. Tirzepatide is a Prescription-Only Medicine, which means a prescriber reviews your individual picture (current weight, health history, how you've tolerated previous doses) before any strength is issued. That's not a bureaucratic hurdle; it's the mechanism that keeps the treatment working safely.

The licensed schedule gives prescribers a framework, not a conveyor belt. Some people spend longer at 5mg because it's controlling appetite effectively and side effects are manageable. Others move through the lower doses quickly and settle at 10mg or 12.5mg for the long term. Reaching 15mg is not the goal for everyone, it's the ceiling, available if clinically appropriate. A fuller look at the Mounjaro titration schedule explains how and when each step is typically considered.

At nume, a named prescriber reads every consultation before a pen is issued or a dose is changed. If you're transferring from another provider or asking for a dose increase, clinical evidence is reviewed, it doesn't happen on request alone. That's the process described on our about us page, and it's what a properly regulated service looks like.

What each strength is actually doing differently

The mechanism is the same across all six doses: tirzepatide activates GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite, as detailed in the NHS tirzepatide medicines page. The difference between strengths is the intensity of that signal. Lower doses tend to produce modest appetite suppression with fewer gastrointestinal effects; higher doses generally produce stronger appetite reduction but carry a higher risk of nausea, vomiting, or reflux, particularly around dose increases.

The SURMOUNT-1 trial, involving 2,539 adults over 72 weeks, found average body-weight reductions of around 20–21% at 15mg, the figures that tend to appear in headlines. Those results were published in the New England Journal of Medicine and formed part of NICE's assessment for TA1026. But the headline figure is a population average across a trial; your individual response at any given dose is shaped by your starting weight, your lifestyle changes alongside treatment, and how your body responds to tirzepatide specifically.

Side effects across all strengths are led by gastrointestinal symptoms. They're usually most noticeable after starting or after moving up a dose, and they tend to settle within days to a couple of weeks. If they don't, that's a conversation for your prescriber, not a reason to quietly skip doses or slow down titration without advice.

The factors that shape which dose a prescriber will consider

Three things tend to drive dosage decisions in practice. First, tolerability: if the current dose is causing persistent nausea or vomiting that isn't settling, rushing upward is counterproductive. Second, response: NICE TA1026 notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing on that dose is reviewed, the treatment isn't indefinite at a dose that isn't working. Third, the clinical picture: comorbidities, other medicines, and how weight loss is progressing all matter.

The question of whether to increase your Mounjaro dose is one our prescribers hear regularly. The honest answer is that it depends on a combination of the above, not on how long you've been waiting or how much someone else has lost. Cost is a real consideration too; if you want context on how pricing varies by dose and provider, the Eli Lilly UK price increase page covers the market background.

For a closer look at specific strengths, the 5mg dose page covers the first maintenance step in detail, and our tirzepatide dosages guide maps the full schedule. If you're unsure how doses are expressed in volume terms, the ml dosage page explains the KwikPen's delivery mechanism clearly.

Private versus NHS: how dosage access differs

On the NHS, tirzepatide is available through a phased rollout under NICE TA1026. As of mid-2026, Cohort 2 (adults with a BMI of 35–39.9 plus four or more of five specified conditions) became eligible, with further cohorts due from around March 2027. Dosage decisions on the NHS happen within the prescribing service you're referred to. Waiting lists vary significantly by area.

Through a private route like nume, clinical eligibility is assessed in the consultation: generally adults with a BMI of 30 or above, or 27 or above with a relevant weight-related condition. If you're suitable, a prescriber determines the appropriate starting or continuing dose, and treatment can be dispatched the same day if the consultation is submitted before midday. The route is explained clearly on the weight-loss treatments overview.

The dosage framework is the same either way; what differs is the access path, the waiting time, and the clinical team involved. If you'd like to understand how your situation maps to current eligibility, check your eligibility with our team, the consultation is free.